연구개발
에피노젠(EPINOGEN)은 부작용이 적은 혁신 항암제 개발을 목표로 합니다.
파이프라인
| Indication | Pipeline | Platform | Development Stage | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Target Validation |
Discovery (Hit to Lead) |
Lead Optimization |
PreClinical Development |
IND enabling |
PhaseⅠ | PhaseⅡ | PhaseⅢ | |||
| 급성 백혈병 (AML) |
PCG-C001 (First-in-Class) |
Chemical |  |
 |
||||||
| 전이성 삼중음성 유방암 (TNBC) |
PCG-C002 (First-in-Class) |
Ab/ADC |  |
|||||||
| PCG-C003 (First-in-Class) |
Chemical |  |
||||||||
| 전이성 대장암 (CC) |
PCG-C004 (First-in-Class) |
Ab/ADC |  |
|||||||
| 헌팅턴씨병 (HD) |
PCG-N001 (First-in-Class) |
Chemical |  |
|||||||
| 소세포폐암 (SCLC) |
PCG-C005 (First-in-Class) |
Ab/ Chemical |
 |
|||||||
| 간암 (LC) |
PCG-C006 (First-in-Class) |
Ab/ADC |  |
|||||||
| 양극성 장애 (ND) |
PCG-N002 (First-in-Class) |
Chemical |  |
|||||||
| 퇴행성 질환 (AD, PD) |
PCG-N003 (First-in-Class) |
Ab/ADC |  |
|||||||